

Original Article

Title page

Complete title: Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: a single-center retrospective study.

Running title: TCZ plus corticosteroids for aged COVID-19 patients.

Authors' affiliations:

Francisco López-Medrano^{1,2*}, María Asunción Pérez-Jacoiste Asín^{1*}, Mario Fernández-Ruiz^{1*}, Octavio Carretero¹, Antonio Lalueza³, Guillermo Maestro de la Calle³, José Manuel Caro⁴, Cristina de la Calle³, Mercedes Catalán⁵, Rocío García-García⁶, Joaquín Martínez-López^{2,7}, Julia Origüen⁸, Mar Ripoll³, Rafael San Juan^{1,2}, Hernando Trujillo⁹, Ángel Sevillano⁹, Eduardo Gutiérrez⁹, Borja de Miguel³, Fernando Aguilar³, Carlos Gómez¹⁰, José Tiago Silva¹, Daniel García-Ruiz de Morales¹, Miguel Saro-Buendía¹, Ángel Marrero-Sánchez¹, Guillermo Chiara-Graciani¹, Héctor Bueno¹¹, Estela Paz-Artal¹², Carlos Lumbreras^{2,3}, José L. Pablos^{2,13}, José María Aguado^{1,2}, on behalf of the H12O Immunomodulation Therapy for COVID-19 Group[&].

1. Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
2. Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Spain.
3. Department of Internal Medicine, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
4. Department of Pharmacy, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
5. Department of Intensive Care Medicine, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
6. Department of Pneumology, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
7. Department of Hematology, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.

8. Department of Emergency Medicine, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
9. Department of Nephrology, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
10. Department of Oncology, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
11. Department of Cardiology, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
12. Department of Immunology, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
13. Department of Rheumatology, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.

* These authors equally contributed to the present work.

& Other members are listed in the Appendix.

ORCID identification numbers:

- Mario Fernández-Ruiz: 0000-0002-0315-8001
 - Francisco López-Medrano: 0000-0001-5333-7529
 - Octavio Carretero: 0000-0003-1839-3853
 - Rocío García-García: 0000-0002-0563-1077
 - Julia Origüen: 0000-0002-6507-0363
 - José L. Pablos: 0000-0001-7229-6005
 - Hernando Trujillo: 0000-0002-3520-1422
 - José María Aguado: 0000-0002-9520-8255
-
- ***Word length*** (excluding title page, abstract, figure legends, tables and references): 3,564
 - ***Number of tables:*** 3
 - ***Number of figures:*** 2
 - ***Number of references:*** 29

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

- **Funding sources:** This work was supported by Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 call COV20/00181) — co-financed by European Development Regional Fund “A way to achieve Europe”. M.F.R. holds a research contract “Miguel Servet” (CP 18/00073) from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III.
- **Corresponding author:** Francisco López-Medrano, MD, PhD, MSc. Unit of Infectious Diseases. Hospital Universitario "12 de Octubre". Centro de Actividades Ambulatorias, 2ª planta, bloque D. Avda. de Córdoba, s/n. Postal code 28041. Madrid, Spain. Phone: +34 913908000. Fax: +34 914695775. E-mail address: flmedrano@yahoo.es

Abstract (250 words)

Background: The role of combination immunomodulatory therapy with systemic corticosteroids and tocilizumab (TCZ) for aged patients with COVID-19-associated cytokine release syndrome remains unclear.

Methods: We conducted a retrospective single-center study including consecutive patients ≥ 65 years that developed severe COVID-19 between March 3 and May 1, 2020 and were treated with corticosteroids at various doses (methylprednisolone [0.5 mg/Kg/12 hours to 250 mg/24 hours]), either alone (“CS group”) or associated to intravenous tocilizumab (400-600 mg, one to three doses) (“CS-TCZ group”). Primary outcome was all-cause mortality by day +14, whereas secondary outcomes included mortality by day +28 and clinical improvement (discharge and/or a ≥ 2 -point decrease on a six-point ordinal scale) by day +14. Propensity score (PS)-based adjustment and inverse probability of treatment weights (IPTW) were applied.

Results: Overall, 181 and 80 patients were included in the CS and CS-TCZ groups. All-cause 14-day mortality was lower in the CS-TCZ group, both in the PS-adjusted (hazard ratio [HR]: 0.34; 95% confidence interval [CI]: 0.17 – 0.68; P -value = 0.002) and IPTW-weighted models (odds ratio [OR]: 0.38; 95% CI: 0.21 – 0.68; P -value = 0.001). This protective effect was also observed for 28-day mortality (PS-adjusted HR: 0.38; 95% CI: 0.21 – 0.72; P -value = 0.003). Clinical improvement by day +14 was higher in the CS-TCZ group in the IPTW analysis only (OR: 2.26; 95% CI: 1.49 – 3.41; P -value < 0.001). The occurrence of secondary infection was similar between both groups.

Conclusions: The combination of corticosteroids and TCZ was associated with better outcomes among patients ≥ 65 years with severe COVID-19.

Keywords: COVID-19; SARS-CoV-2; tocilizumab; corticosteroids; therapy; immunomodulation; outcome; mortality.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), is a novel beta-coronavirus first identified in December 2019 in Wuhan, China (1). Most cases of SARS-CoV-2 infection have a mild-to-moderate course, although a significant proportion of patients will ultimately develop acute respiratory distress syndrome (ARDS) (2), which carries a high mortality rate (3). Older age has been consistently identified as a risk factor for death and poor outcomes in COVID-19. For example, a report of 72,314 cases from China found case-fatality rates of 8% and 15% for patients aged 70-79 years and >80 years, respectively, in contrast with an overall rate as low as 2.3% for the global cohort (4). In the United Kingdom the risk of death for COVID-19 patients older than 80 years was 20-fold higher than those between 50 and 59 (5).

The pathogenesis of severe COVID-19 and associated ARDS involves a hyperinflammatory status resembling the cytokine storm release syndrome observed in patients with influenza or immune-mediated diseases (6). Therefore, a growing number of immunomodulatory therapies are being tested to counteract this deleterious inflammatory response (7-15). One of the most mature approaches at this point of the pandemic involves the off-label use of the humanized anti-interleukin (IL)-6 receptor monoclonal antibody tocilizumab (TCZ) (9-11), on the basis of the previous experience with patients receiving chimeric antigen receptor T-cell therapy (16). On the other hand, a recently published randomized controlled trial (RCT) has demonstrated a survival benefit from corticosteroid therapy in patients with ARDS (17). In the setting of COVID-19, a meta-analysis comprising more than 1,700 participants from 7 RCTs reported a reduction in 28-day mortality of 34% with the administration of systemic corticosteroids as compared with usual care or placebo(18).

Regardless this emerging evidence, studies comparing both TCZ- and corticosteroids-based therapeutic strategies are scarce (19). The additional benefit to be expected from the sequential use of TCZ in the context of previous use of corticosteroids has been recently raised (20). This question is particularly relevant for older patients, which have an increased risk of death due to COVID-19 but also of developing adverse events related to immunomodulatory

agents, such as superinfections. The shortage of TCZ during the first weeks of the pandemic in our setting allowed us to perform a comparative study focused on the vulnerable population of individuals aged 65 years and older with the objective to analyze the value of adding TCZ to systemic corticosteroid therapy (as compared to corticosteroids alone) in patients with severe COVID-19 pneumonia.

Materials and Methods

Study population and design

This retrospective cohort study was conducted at the University Hospital “12 de Octubre” a 1,300-bed tertiary care center located in the urban area of Madrid (Spain). The Clinical Research Ethics Committee approved the study protocol and granted a waiver of informed consent due to its observational design. The research was performed in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

The study population included patients ≥ 65 years consecutively admitted due to severe COVID-19 pneumonia from March 3 to May 1, 2020, that received intravenous (IV) corticosteroids alone (“CS group”) or associated to IV TCZ (“CS-TCZ group”) as immunomodulatory therapy. For analysis purposes, the date of administration of the first dose of any of these agents was considered as day 0. To minimize potential survivor bias, patients that died within the first 24 hours (i.e. day +1) were excluded. Participants were followed-up to discharge, death (whichever occurred first), or June 30, 2020.

Demographics and comorbidities; symptoms at presentation; vital signs, laboratory values and radiological features at day 0; use of antiviral therapy; treatment-related adverse events; and outcomes were collected from electronic medical records using a standardized case report form. Respiratory function was assessed by the pulse oximetry oxygen saturation/fraction of inspired oxygen (SpO_2/FiO_2) ratio. The National Early Warning Score (NEWS) was calculated at admission. Dynamic changes over time in the clinical status were assessed according to a six-point ordinal scale: 1.- discharged to home; 2.- admitted to the hospital, not requiring supplemental oxygen; 3.- admitted to the hospital, requiring low-flow supplemental oxygen ($FiO_2 < 40\%$); 4.- admitted to the hospital, requiring high-flow supplemental oxygen ($FiO_2 \geq 40\%$) or non-invasive mechanical ventilation; 5.- admitted to the hospital, requiring invasive mechanical ventilation (IMV), extracorporeal membrane oxygenation (ECMO), or both; and 6.- death.

Antiviral and immunomodulatory therapies

According to clinical practice guidelines issued by the Spanish Ministry of Health during the study period ([21](#)), antiviral regimens could include co-formulated lopinavir/ritonavir (LPV/r) (200/100 mg twice daily for up to 14 days), hydroxychloroquine (HCQ) (400 mg twice for the first day, followed by 200 mg twice daily for 5-10 days), and subcutaneous (SC) interferon (IFN)- β

(250 µg every 48 hours). All these drugs were used off-label and oral or written informed consent was previously obtained. In addition, some patients received IV remdesivir (200 mg during the first day, followed by 100 mg daily for 5 to 10 days) in the context of an ongoing clinical trial. The use of empirical antibiotic therapy was contemplated for patients admitted due to COVID-19 pneumonia. Most patients received thromboprophylaxis with low-molecular-weight heparin.

Due to shortages in TCZ supply, a multidisciplinary committee that included clinical specialties and the Department of Pharmacy was created to facilitate and standardize therapeutic decisions, as detailed elsewhere. The committee held daily meetings (except for the weekends) throughout the pandemic period. The first meeting took place on March 18, two days after the introduction in the local protocol of TCZ as a therapeutic option for COVID-19. The off-label use of TCZ was considered for patients potentially eligible for intensive care unit (ICU) admission, with bilateral or rapidly progressive infiltrates in chest X-ray or computerized tomography (CT) scan, and fulfilling one or more of the following criteria: respiratory rate >30 bpm and/or pulse oximetry oxygen saturation (SpO₂) <92% on room air, C-reactive protein (CRP) level >10 mg/dL, IL-6 level >40 pg/mL, and/or D-dimers >1,500 ng/mL. Exclusion criteria included the presence of liver function abnormalities (alanine aminotransferase and/or aspartate aminotransferase levels >5 times the upper normal limit), uncontrolled bacterial or fungal infection, or acute diverticulitis or bowel perforation. An initial IV 400 mg (if body weight <75 Kg) or 600 mg (if body weight ≥75 Kg) dose was administered as one-hour infusion. Until March 26, a second 400 mg dose was routinely administered 12 hours later, whereas a third dose could be given after 24 hours from the first infusion for selected patients according to the criteria of the treating physician (22). After that date, a single TCZ dose was administered according to the updated recommendations of the Ministry of Health of Spain, on the basis of dosing regimens approved for rheumatologic diseases (23).

The local protocol took into account the use of corticosteroids already in its initial version (issued on March 16) for patients with severe COVID-19 pneumonia fulfilling the same inclusion criteria established for the initiation of TCZ, when the latter agent was not available or in the presence of any of the exclusion criteria detailed above. Different dosing regimens were considered (IV methylprednisolone 0.5-1 mg/Kg daily for ≤5 days or as pulses of 100 to 250 mg

for 3 days). Beginning in April 2020, the prescription of corticosteroids was generalized for patients presenting to the Emergency Room with COVID-19 pneumonia and SpO₂ <92% on room air, regardless of the subsequent administration of TCZ.

Design of study groups

Given the relatively low baseline prescription rate and the marked surge in demand early after the beginning of the pandemic, there was a shortage of TCZ during the first weeks of March. The interdisciplinary committee decided to distribute, on a daily basis, the available doses according to three principles: a) the fulfillment of the previously detailed inclusion and exclusion criteria; b) the absence of a short-term life-threatening condition; c) and, providing that both previous criteria were met, the drug was preferably administered to those patients with a longer life expectancy. As a result, during the month of March TCZ was more commonly prescribed to younger patients, whereas corticosteroids alone were widely used for patients ≥65 years. As the incidence of SARS-CoV-2 infection declined and the supply of TCZ increased, an increasing proportion of patients ≥65 years received this immunomodulatory drug from April, 2020.

This circumstance allowed us to compare two quasi-contemporary cohorts of aged patients treated with different immunomodulatory regimens: corticosteroids alone during the first period (March, 2020 ["CS group"]), and corticosteroids associated to TCZ during the second period (April and May, 2020 ["CS-TCZ group"]).

Study outcomes

The *primary outcome* was all-cause mortality by day +14 after the first dose of the immunomodulatory therapy. *Secondary outcomes* included all-cause mortality by day +28 and clinical improvement by day +14 (defined as discharge to home and/or a decrease of ≥2 points from day 0 on the six-point ordinal scale).

Statistical analysis

Quantitative data were shown as the mean and standard deviation (SD) or the median with interquartile range (IQR), whereas qualitative variables were expressed as absolute and relative frequencies. Categorical variables were compared using the χ^2 test. Student's t-test or Mann-Whitney U test were applied for continuous variables, as appropriate. Baseline factors predicting clinical improvement by day +14 were analyzed by means of logistic regression, with associations expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Collinearity

among explanatory variables was assessed with the variance inflation factor (VIF). Survival probabilities were graphically depicted according to the Kaplan-Meier method and compared with the log-rank test. A landmark analysis restricted to survivors that remained hospitalized by day +4 was performed to take into account potential survivor bias. Cox regression with backward stepwise selection was used to assess the effects of different variables on mortality rates by days +14 and +28. Associations were expressed as hazard ratios (HR) and 95% CIs. To overcome the limitation posed by the nonrandomized design of the study, we calculated the propensity score (PS) for receiving TCZ therapy in association to corticosteroids (versus corticosteroids alone) given the patient's characteristics. This PS was constructed using a non-parsimonious logistic regression, with the inclusion in the CS or CS-TCZ groups considered as the dependent variable and all potential confounders entered as covariates. The ability of the resulting PS to predict the observed data was calculated by means the area under the receiver operating characteristic curve (auROC), and calibration was assessed with the Hosmer-Lemeshow goodness-of-fit test. The PS was applied in two ways to correct for baseline disparities between groups: as a covariable for regression adjustment, and as inverse probability of treatment weights (IPTW). Statistical analysis was performed with SPSS version 22.0 (IBM Corporation® Armonk, NY).

Results

Clinical characteristics of study groups

Overall, 275 patients ≥ 65 years admitted to our center with severe COVID-19 pneumonia during the study period received systemic corticosteroids. Eighty-one of them were also sequentially treated with TCZ after a median interval of 1 day (IQR: 0 - 5). Fourteen patients that died within the first 24 hours from the initiation of immunomodulatory therapy were excluded. Therefore, 181 and 80 patients were included within the CS and CS-TCZ groups, respectively.

The mean age of the global cohort was 77.2 ± 7.7 years, 147 patients (56.3%) were males, and 240 (92.0%) of Caucasian ethnicity. The median Charlson comorbidity index was 4.0 (IQR: 3 - 5). Regarding symptoms at presentation, cough was reported by 198 patients (75.9%), fever by 187 (71.6%), and dyspnea by 180 (69.0%). Among 238 patients with available data, median NEWS at admission was 4 (IQR: 2 - 6). Radiological lung involvement was diffuse in 179 patients (68.6%). All-cause 14- and 28-day mortality rates were 37.2% (97/261) and 41.4% (108/261), respectively, whereas clinical improvement by day +14 was observed in 38.3% (100/216) of patients.

We compared the clinical characteristics of patients receiving systemic corticosteroids alone or in association to TCZ. As expected in view of the evolving prescription practices over time in our center, the majority of those within the CS group were treated during the month of March (97.2% [176/181]), whereas most of patients in the CS-TCZ group were treated during April and May (92.5% [74/80]). Patients in the CS group were significantly older and had a higher prevalence of comorbid conditions, mainly obesity, chronic lung and heart disease and dementia. The NEWS at admission was also higher in this group (**Table 1**). Regarding clinical status at day 0, patients in the CS-TCZ group had a poorer respiratory status (as assessed by the SpO₂/FiO₂ ratio), lower lymphocyte counts and higher lactate dehydrogenase (LDH) levels, and presented more commonly with bilateral alveolar involvement in the chest X-ray. The use of LPV/r and IFN- β was more common in the CS group, whereas patients in the CS-TCZ group were more likely to be treated with remdesivir (**Table 2**).

Twenty-nine patients (11.1%) were admitted to the ICU at some point during the index hospitalization (5.5% [10/181] in the CS group and 23.8% [19/80] in the CS-TCZ groups). Immunomodulation was initiated prior to or on the same day of ICU admission in 48.3% (14/29)

of these patients, within a median interval of 1 day (IQR: 0 - 5). In the overall cohort there were no differences between patients admitted or not admitted to the ICU in 14-day (27.6% [8/29] vs. 38.4% [89/232]; P -value = 0.258) or 28-day mortality rates (34.5% [10/29] vs. 42.2% [98/232], respectively; P -value = 0.424).

Study outcomes

All-cause mortality by day +14 (primary outcome) was significantly lower in the CS-TCZ as compared to the CS group (22.5% [18/80] vs. 43.6% [79/181]; log-rank P -value <0.001) (**Figure 1a**). Regarding secondary outcomes, all-cause mortality by day +28 was also lower for patients within the CS-TCZ group (27.5% [22/80] vs. 47.5% [86/181]; log-rank P -value <0.001) (**Figure 1b**). A landmark analysis on those patients surviving ≥ 4 days ($n = 208$) confirmed the benefit survival by day +28 among patients in the CS-TCZ group (**Figure 2**). There were no significant differences in the rate of clinical improvement by day +14 (45.0% [36/80] vs. 35.4% [64/181] in the CS-TCZ and CS groups; P -value = 0.140).

PS-adjusted analysis

In view of the presence of baseline imbalances between both groups, we constructed the PS for receiving TCZ associated to corticosteroids (CS-TCZ group) on the basis of those clinical and analytical variables present at day 0. The following measured predictors were included: age, Caucasian ethnicity, obesity, chronic lung disease, chronic heart disease, dementia, Charlson comorbidity index, cough at presentation, time since symptom onset, SpO₂/FiO₂ ratio <316 at day 0, lymphocyte count and LDH level at day 0, and the presence of bilateral alveolar infiltrates at day 0. The auROC of the PS was 0.849 (95% CI: 0.798 – 0.899), with a P -value = 0.128 in the Hosmer-Lemeshow test, suggesting excellent discriminative capacity and model calibration, respectively.

Patients in the CS-TCZ group experienced a lower 14-day all-cause mortality in the PS-adjusted model (HR: 0.34; 95% CI: 0.17 – 0.68; P -value = 0.002), after further adjustment for the receipt of antiviral agents (HR: 0.43; 95% CI: 0.25 – 0.74; P -value = 0.002), and in the IPTW-adjusted model (OR: 0.38; 95%: 0.21 – 0.68; P -value = 0.001). Regarding secondary outcomes, 28-day mortality was also significantly lower in the CS-TCZ group applying PS and IPTW adjustment, whereas clinical cure by day +7 was higher in the IPTW-adjusted model only (**Table 3**). These associations remained essentially unchanged in the landmark analysis restricted to hospitalized

patients surviving at +4 (**Table S1** in Supporting Material).

Treatment-related adverse events

The diagnosis of superinfection beyond day 0 was made in 6.1% (11/181) and 3.8% (3/80) of patients in the CS and CS-TCZ groups, respectively (P -value = 0.561). Hypertriglyceridemia (>200 mg/dL) was more common in the CS-TCZ group (18.8% [15/80] vs. 0.0% [0/181]; P -value <0.0001). Elevation in liver function tests was observed in 3.9% (7/181) and 8.8% (7/80) of patients in the CS and CS-TCZ groups, respectively (P -value = 0.136).

Discussion

An increasing number of studies (including RCTs) supports the use of systemic corticosteroids to reduce mortality in severe forms of COVID-19 (7), although the incremental effect of adding TCZ to this therapeutic approach remains unclear. The shortage of TCZ at the initial stages of the pandemic in our setting offered the opportunity to compare two consecutive cohorts of patients ≥ 65 years treated with different immunomodulation strategies. Patients in the CS group were older and had a greater comorbidity burden than those in the CS-TCZ group, a difference that may reflect the reluctance of treating physicians to initiate IL-6 blockade in this aged population due to concerns about potential adverse events and the greater clinical experience with the use of short courses of corticosteroids. Indeed, only two patients older than 90 years underwent combination therapy, whereas 8.3% of those in the CS group were in this age stratum. Another difference was the proportion of patients admitted to the ICU during the index hospitalization (5.5% and 23.8% in the CS and CS-TCZ groups), which is likely due the evolving availability of ICU resources throughout the study period, with less beds available at the peak of the pandemic in March 2020 in coincidence with the shortage of TCZ. Nevertheless, we found not differences in mortality between patients admitted or not admitted to the ICU.

Combination therapy with corticosteroids and TCZ was found to be associated in the present cohort with lower mortality rates at 14 and 28 days as compared to the use of corticosteroids alone. The baseline imbalances in terms of age and comorbidities mentioned above would have favored the CS-TCZ group, although the clinical status at day 0 was worse in these patients (as reflected by their lower $\text{SpO}_2/\text{FiO}_2$ ratio and lymphocyte count, higher LDH level, more common bilateral alveolar involvement in the chest X-ray, and longer interval from symptom onset). The experimental use of remdesivir—a direct-acting antiviral agent inhibiting the SARS-CoV-2 RNA-dependent RNA polymerase that has been demonstrated to shorten the time to recovery (24)—was more common in the CS-TCZ group (albeit it was administered to only 8.2% of patients). In addition, more patients in the CS group received IFN- β , in keeping with the recommendations contained in the institutional protocol during the first weeks of March. Therefore, we applied PS adjustment and IPTW to take into account these differences operating in opposite senses, and still found significant risk reductions in the primary study outcome ranging from 57% to 66% (according to the adjusted model) in favor of the combination of corticosteroids and TCZ. On the

other hand, and despite the lack of apparent impact in the crude comparison, the odds for achieving clinical response by day +14 was also significantly higher in the CS-TCZ group after balancing potential confounders by IPTW. Nevertheless, this association should be taken with caution since it was not confirmed in PS-adjusted models.

Although it was to be expected that the old age of our patients (77.2 ± 7.7 years) would have put them at an increased risk of TCZ-associated adverse events, no significant differences were found in the occurrence of bacterial or fungal infectious complications between study groups. No apparent impact on the risk of secondary bacterial infection among patients treated with TCZ and corticosteroids (versus no immunomodulatory therapy) was reported from a recently published multicenter study either(25). The increase of lipid levels is a well-known event in patients with rheumatoid arthritis receiving long-term TCZ therapy(26), and the development of TCZ-induced hypertriglyceridemia has been also observed in the setting of COVID-19(27).

Only few previous studies have investigated the effectiveness of the association between TCZ and corticosteroids for severe COVID-19 pneumonia. Hazbun et al. described a small series of patients undergoing mechanical ventilation with no control group (28). Ramiro et al. compared a two-step approach based on high-dose methylprednisolone followed by TCZ if needed in non-responders with a historic control group receiving standard of care alone. The authors found that this sequential strategy accelerated respiratory recovery, decreased in-hospital mortality and reduced the likelihood of invasive mechanical ventilation (29). On the contrary, Rodríguez-Baño et al. reported no differences in the risk of intubation or death among patients treated with combination therapy(25).

There are a number of limitations in our study to be acknowledged. First, due to its retrospective observational design, the impact of unmeasured confounders cannot be completely ruled out, even after PS-based and IPTW adjustments. As discussed above, the direction of potential bias is not obvious in view of the nature of baseline imbalances. Likewise, we have attempted to minimize the risk of survivor bias by excluding those patients dying within the first 24 hours and by means of landmark survival analyses. Second, different regimens of corticosteroids and TCZ were used, preventing us to conclude on optimal dosing strategies. Finally, the single-center design hampers the applicability of findings to other settings.

The Infectious Disease Society of America has recently highlighted in their evidence-based guidelines ([19](#)) that RCTs constitute the optimal framework to evaluate the efficacy and safety of newer therapies for COVID-19. Indeed, a number of ongoing trials are aimed at comparing TCZ versus corticosteroids (NCT04345445 and NCT04377503), corticosteroids alone or associated to TCZ (NCT04476979), and TCZ versus TCZ plus corticosteroids (NCT04486521). Until the results of these RCTs become available, observational studies might be useful to guide clinical decisions providing that caution is applied before concluding on potential causation. In conclusion, the present experience suggests that the use of IV TCZ on top of corticosteroid therapy may be more useful than corticosteroids alone to improve outcomes in patients ≥ 65 years with hyperinflammatory status triggered by SARS-CoV-2 infection.

Appendix

Other members of the H12O Immunomodulation Therapy for COVID-19 Group:

Unit of Infectious Diseases: Manuel Lizasoain, Tamara Ruiz-Merlo, Patricia Parra; Department of Pharmacy: José Miguel Ferrari; Department of Pneumology: Javier Sayas Catalán, Eva Arias Arias; Department of Nephrology: Fernando Caravaca, Amado Andrés, Manuel Praga; Department of Rheumatology: María Martín-López; Department of Hematology: Denis Zafra, Cristina García Sánchez; Department of Oncology: Carmen Díaz-Pedroche, Flora López, Luis Paz-Ares; Department of Intensive Care Medicine: Jesús Abelardo Barea Mendoza, Paula Burgueño Laguía, Helena Domínguez Aguado, Amanda Lesmes González de Aledo, Juan Carlos Montejo; Department of Emergency Medicine: Antonio Blanco Portillo, Laura Castro Reyes, Manuel Gil-Mosquera, José Luis Montesinos Díaz, Isabel Fernández-Marín; Department of Immunology: Óscar Cabrera-Marante, Antonio Serrano-Hernández, Daniel Pleguezuelo, Édgar Rodríguez de Frías, Paloma Talayero, Laura Naranjo-Rondán, Ángel Ramírez-Fernández, María Lasa-Lázaro, Daniel Arroyo-Sánchez, Rocío Laguna-Goya; Department of Microbiology: Rafael Delgado, María Dolores Folgueira.

Transparency declaration

All the authors declare no potential conflict of interest regarding this study.

Acknowledgements

The authors would like to acknowledge all the health-care workers involved in the response to the current pandemic in our hospital and, singularly, those who suffered COVID-19.

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020.
3. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020.
4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020.
5. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020.
6. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020.
7. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med*. 2020.
8. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. *Lancet Rheumatol*. 2020;2(6):e325-e31.
9. Canziani LM, Trovati S, Brunetta E, Testa A, De Santis M, Bombardieri E, et al. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. *J Autoimmun*. 2020:102511.
10. Rossotti R, Travi G, Ughi N, Corradin M, Baiguera C, Fumagalli R, et al. Safety and Efficacy of Anti-IL6-Receptor Tocilizumab Use in Severe and Critical Patients Affected by Coronavirus Disease 2019: A Comparative Analysis. *J Infect*. 2020.

11. Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. *Ann Rheum Dis*. 2020.
12. Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, et al. Use of Baricitinib in Patients with Moderate and Severe COVID-19. *Clin Infect Dis*. 2020.
13. Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. *J Allergy Clin Immunol*. 2020;146(1):137-46 e3.
14. Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. *Eur Rev Med Pharmacol Sci*. 2020;24(7):4040-7.
15. Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. *JAMA Netw Open*. 2020;3(6):e2013136.
16. Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. *Expert Rev Clin Immunol*. 2019;15(8):813-22.
17. Villar J, Ferrando C, Martinez D, Ambros A, Munoz T, Soler JA, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir Med*. 2020;8(3):267-76.
18. Group WHOREAfC-TW, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA*. 2020.
19. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. *Clin Infect Dis*. 2020.
20. Schulert GS. Can tocilizumab calm the cytokine storm of COVID-19? *Lancet Rheumatol*. 2020.

21. Ministerio de Sanidad, Centro de Coordinación de Alertas y Emergencias Sanitarias. Documento técnico de manejo clínico de pacientes con enfermedad por el nuevo coronavirus (COVID-19) [in Spanish]. Available at: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Protocolo_manejo_clinico_ah_COVID-19.pdf [accessed July 29, 2020].
22. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. *Oncologist*. 2018;23(8):943-7.
23. Ministerio de Sanidad. Agencia Española de Medicamentos y Productos Sanitarios. Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 (version March 27, 2020) [In Spanish] Available at: <https://www.aemps.gob.es/laAEMPS/docs/medicamentos-disponibles-SARS-CoV-2-27-3-2020.pdf?x19374> [Accessed July 29, 2020]. .
24. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N Engl J Med*. 2020.
25. Rodriguez-Bano J, Pachon J, Carratala J, Ryan P, Jarrin I, Yllescas M, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). *Clin Microbiol Infect*. 2020.
26. Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2016;75(10):1806-12.
27. Morrison AR, Johnson JM, Ramesh M, Bradley P, Jennings J, Smith ZR. Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab. *J Med Virol*. 2020.
28. Hazbun ME, Faust AC, Ortegón AL, Sheperd LA, Weinstein GL, Doebele RL, et al. The Combination of Tocilizumab and Methylprednisolone Along With Initial Lung Recruitment Strategy in Coronavirus Disease 2019 Patients Requiring Mechanical Ventilation: A Series of 21 Consecutive Cases. *Crit Care Explor*. 2020;2(6):e0145.
29. Ramiro S MR, Magro-Checa C, van Dongen CMP, Dormans T, Buijs J, Gronenschild M, de Kruif MD, van Haren EHJ, van Kraaij T, Leers MPG, Peeters R, Wong DR, Landewé RBM.

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. *Ann Rheum Dis.* 2020.

Tables

Table 1. Demographics and clinical in both study groups.

	CS group (n = 181)	CS-TCZ group (n = 80)	P-value
Age at diagnosis, years [mean ± SD]	78.4 ± 7.7	74.4 ± 7.0	<0.0001
Male gender [n (%)]	102 (56.4)	45 (56.2)	0.988
Ethnicity [n (%)]			0.029
Caucasian	173 (95.6)	71 (88.8)	
Latino	5 (2.8)	9 (11.2)	
Other	3 (1.7)	0 (0.0)	
Comorbidities [n (%)]			
Obesity	74 (40.9)	10 (12.5)	<0.0001
Chronic lung disease ^a	61 (33.7)	14 (17.5)	0.008
Chronic heart disease ^b	45 (24.9)	6 (7.5)	0.001
Diabetes mellitus	44 (24.3)	22 (27.5)	0.585
Malignancy	27 (14.9)	13 (16.2)	0.783
End-stage renal disease	22 (12.2)	4 (5.0)	0.073
Dementia	19 (10.5)	0 (0.0)	0.003
Lower limb peripheral arterial disease	14 (7.7)	5 (6.2)	0.670
Solid organ transplantation	12 (6.7)	6 (7.5)	0.807
Cerebrovascular disease	11 (6.1)	4 (5.0)	1.000
Chronic liver disease	3 (1.7)	3 (3.8)	0.375
Charlson comorbidity index [median (IQR)]	5 (3 - 6)	4 (3 - 5)	<0.0001
Previous systemic corticosteroid therapy [n (%)]	23 (12.7)	5 (6.2)	0.120
Current or previous smoking [n (%)]	69 (38.1)	28 (35.0)	0.630
Symptoms at presentation [n (%)]			
Cough	144 (79.6)	54 (67.5)	0.036
Fever	140 (77.3)	47 (58.8)	0.002
Dyspnoea	122 (67.4)	58 (72.5)	0.412
Diarrhoea	55 (30.4)	19 (23.8)	0.273
Myalgia	53 (29.3)	20 (25.0)	0.477
Expectoration	48 (26.5)	13 (16.2)	0.071
Impaired consciousness	15 (8.3)	4 (5.0)	0.346
NEWS at admission [median (IQR)] ^c	3 (1 - 5)	6 (3.5 - 7)	<0.0001
Interval from symptom onset to day 0, days [mean ± SD] ^d	10 (7 - 13)	11 (9 - 16)	0.001
Interval from hospital admission to day 0, days [mean ± SD] ^d	4 (1 - 6)	3 (1 - 8)	0.432

CS: corticosteroids; IQR: interquartile range; NEWS: National Early Warning Score; SD: standard deviation; TCZ: tocilizumab.

^a Includes chronic obstructive pulmonary disease, asthma, obstructive sleep apnea.

^b Includes congestive heart failure and coronary heart disease.

^c Data available for 236 patients.

^d Day 0 refers to the date of administration of the first dose of immunomodulatory therapy (either corticosteroids or tocilizumab).

Table 2. Vital signs and laboratory values at the initiation of immunomodulation, and other therapies used in both study groups.

	CS group (n = 181)	CS-TCZ group (n = 80)	P-value
Vital signs at day 0			
Axillary temperature, °C [mean ± SD]	37.5 ± 0.9	37.2 ± 0.9	0.010
Respiratory rate, rpm [mean ± SD]	24.3 ± 7.4	27.5 ± 6.5	0.090
Heart rate, bpm [mean ± SD]	88.4 ± 17.5	88.2 ± 16.5	0.923
SpO ₂ /FiO ₂ ratio [mean ± SD]	231.9 ± 107.8	191.9 ± 84.8	0.003
SpO ₂ /FiO ₂ ratio <316 [n (%)] ^a	111 (75.5)	65 (89.0)	0.018
Laboratory values at day 0			
Leucocytes, x 10 ⁹ cells/L [median (IQR)]	6.0 (4.8 – 8.3)	8.6 (6.1 – 13.5)	<0.0001
Lymphocytes, x 10 ⁹ cells/L [median (IQR)]	0.8 (0.5 – 1.0)	0.6 (0.4 – 0.8)	0.028
CRP, mg/dL [mean ± SD]	15.9 ± 9.7	14.8 ± 8.4	0.406
CRP >10 mg/dL [n (%)]	108 (68.8)	51 (67.1)	0.796
CRP >15 mg/dL [n (%)]	72 (45.9)	32 (42.1)	0.589
LDH, U/L [mean ± SD] ^b	412 ± 138	491 ± 200	0.002
LDH >350 U/L [n (%)] ^b	115 (65.3)	60 (75.9)	0.091
Ferritin, ng/mL [median (IQR)] ^c	1,034 (464 – 2,028)	1,264 (640.3 – 1,080)	0.253
D-dimers, ng/mL [median (IQR)] ^d	872 (591 – 1,629.5)	1,323.5 (627.5 – 5,526.8)	0.088
Chest X-ray at day 0 [n (%)]^e			0.017
Bilateral interstitial infiltrates	113 (65.7)	36 (46.2)	
Bilateral alveolar infiltrates	54 (31.4)	40 (51.3)	
Unilateral alveolar infiltrate	2 (1.2)	0 (0.0)	
Other	3 (1.7)	2 (2.6)	
Other treatments administered [n (%)]			
LPV/r	102 (56.4)	22 (27.5)	<0.0001
HQC	162 (89.5)	76 (96.2)	0.074
Azithromycin	130 (71.8)	63 (78.8)	0.370
IFN-β	34 (18.8)	2 (2.6)	0.001
Remdesivir	1 (0.6)	7 (8.8)	0.001

CS: corticosteroids; HCQ: hydroxychloroquine; IFN-β: interferon-β; IQR: interquartile range; LDH: lactate dehydrogenase; LPV: lopinavir/ritonavir; SD: standard deviation; TCZ: tocilizumab.

^a Equivalent to a partial oxygen pressure (PaO₂)/FiO₂ ratio <300.

^b LDH levels at day 0 available for 255 patients.

^c Ferritin levels at day 0 available for 81 patients.

^d D-dimer levels at day 0 available for 99 patients.

^e Chest X-ray at day 0 available for 250 patients.

Table 3. Effect of combination immunomodulatory therapy (corticosteroids plus TCZ) versus corticosteroids alone on primary and secondary study outcomes in different models.

Model	All-cause mortality by day +14		All-cause mortality by day +28		Clinical improvement by day +14	
	Effect estimate (95% CI)	P-value	Effect estimate (95% CI)	P-value	Effect estimate (95% CI)	P-value
Crude	HR: 0.42 (0.25 – 0.69)	0.001	HR: 0.44 (0.28 – 0.71)	0.001	OR: 1.49 (0.88 – 2.56)	0.141
Adjusted for PS alone ^a	HR: 0.34 (0.17 – 0.68)	0.002	HR: 0.38 (0.21 – 0.72)	0.003	OR: 2.04 (1.01 – 4.13)	0.048
Adjusted for PS and other clinical covariates ^b	HR: 0.43 (0.25 – 0.74)	0.002	HR: 0.47 (0.29 – 0.77)	0.003	OR: 1.41 (0.79 – 2.51)	0.243
Weighted by IPTW	OR: 0.38 (0.21 – 0.68)	0.001	OR: 0.42 (0.24 – 0.74)	0.003	OR: 2.26 (1.49 – 3.41)	<0.001

CI: confidence interval; HR: hazard ratio; inverse probability of treatment weights; OR: odds ratio; PS: propensity score.

^aThe propensity score for receiving TCZ therapy in association to corticosteroids (versus corticosteroids alone) included the following variables: age, Caucasian ethnicity, obesity, chronic lung disease, chronic heart disease, dementia, Charlson comorbidity index, cough at presentation, time since symptom onset, SpO₂/FiO₂ ratio <316 at day 0, lymphocyte count at day 0, LDH level at day 0, and bilateral alveolar infiltrates at day 0.

^bModel additionally adjusted for the receipt of LPV/r, IFN-β or remdesivir.


Figure legends

- **Figure 1:** Comparison of Kaplan-Meier survival curves in patients included in the CS and CS-TCZ groups: **(a)** by day +14 (primary study outcome); **(b)** by day +28 (secondary study outcome). Log-rank *P*-values <0.001 for both comparisons. CS: corticosteroids; TCZ: tocilizumab.
- **Figure 2.** Landmark survival analysis on patients surviving by day +4. Log-rank test *P*-value = 0.0024. CS: corticosteroids; TCZ: tocilizumab.


Supporting Material

Supplementary Results


- **Table S1.** Effect of combination immunomodulatory therapy (corticosteroids plus TCZ) versus corticosteroids alone on primary and secondary study outcomes in the landmark analysis of surviving patients that remained hospitalized by day +4 (n = 208).

a)**Number at risk**

CS	181	181	146	116	89	75	59	50
CS-TCZ	80	80	73	67	58	53	45	36

b)**Number at risk**

CS	181	146	89	59	47	26	21	11
CS-TCZ	80	73	58	45	32	27	19	15



Number at risk

CS	180	180	146	87	57	45	24	19	9
CS-TCZ	81	80	73	55	42	29	24	16	12